Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA

Marks significant milestone for breakthrough biologic to treat rare blood cancers

Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial

The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36

EnteroBiotix completes enrollment in landmark microbiome trial for stem cell transplant patients

The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation

Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors

Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile

Roche reports Phase III persevERA breast cancer trial results

Giredestrant shows promise despite missing primary goal

Pfizer’s experimental atopic dermatitis drug shows strong Phase 2 results

The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75

Codis expands UK manufacturing with groundbreaking spray dryer

The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027

Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation

Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings

KIMS Hospitals makes bold entry into Bengaluru with two new super-speciality units

The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management

Lonza expands manufacturing pact with Genetix to meet rising demand for gene therapy ZYNTEGLO